A- A A+

Iran. A new delivery model to increase adherence to methadone maintenance treatment.

Komasi S, Saeidi M, Sariaslani P, Soroush A.

Caspian J Intern Med. 2018 Winter;9(1):104-105. doi: 10.22088/cjim.9.1.104.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771370/

Social and structural barriers for adherence to methadone maintenance treatment among Vietnamese opioid dependence patients.

Tran BX, Nguyen LH, Tran TT, Latkin CA (2018) PLoS ONE 13(1): e0190941. doi.org/10.1371/journal.pone.0190941

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0190941

USA. Bad Weather Take Home Doses for Opioid Treatment Program Patients

We’ve had some snowy days in my area, and this means administrators at our opioid treatment program must decide if we should provide extra take home doses to patients for the days when travel will be treacherous.

Because take home doses are closely regulated at opioid treatment programs, both for methadone and buprenorphine, we must get special permission from state and federal regulatory agencies to give extra take home doses. We do this by submitting what’s called an “exception request.” This is an online form where we describe why we are requesting an extra take home, and for whom it will apply. Part of our job is assuring the authorities we won’t give extra take homes to patients who can’t manage them safely.

Ultimately, it’s up to me, the medical director, to decide the risk level of each patient. Which is more dangerous, driving on snowy roads to get to the opioid treatment program to dose, or having an extra take home bottle of medication? I need input from the staff to make the best decisions, so this can be time consuming.

Admittedly, my program failed our patients this last week. (Janaburson’s Blog, 22.01.2018)

https://janaburson.wordpress.com/2018/01/22/bad-weather-take-home-doses-for-opioid-treatment-program-patients/

A pilot feasibility randomised controlled trial of an adjunct brief social network intervention in opiate substitution treatment services.

Day E, Copello A, Seddon JL, Christie M, Bamber D, Powell C, Bennett C, Akhtar S, George S, Ball A, Frew E, Goranitis I, Freemantle N.

BMC Psychiatry. 2018 Jan 15;18(1):8. doi: 10.1186/s12888-018-1600-7.

https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-018-1600-7

USA-New York. Opioid Addiction Knows No Color, but Ist Treatment Does

On a street lined with garbage trucks, in an industrial edge of Brooklyn, dozens of people started filing into an unmarked building before the winter sun rose. Patients gather here every day to visit the Vincent Dole Clinic, where they are promised relief from their cravings and from the constant search for heroin on the streets. (NYT, 12.01.2018)

https://www.nytimes.com/2018/01/12/nyregion/opioid-addiction-knows-no-color-but-its-treatment-does.html

USA. Buprenorphine and Methadone Dispensing in New York City.

Tuazon E, Kunins H, Paone D.

New York City, Department of Health and Mental Hygiene: Epi Data Brief (96); November 2017.

Buprenorphine and methadone are opioid agonist medications that are both safe and effective in the treatment of opioid use disorders . Methadone dispensing has been available through certified New York State Office of Alcoholism and Substance Abuse Services (OASAS) Opioid Treatment Programs in New York City (NYC) since the late 1970s.

Buprenorphine has been approved for treatment of opioid use disorders since 2002, and is now available by prescription from physicians, nurse practitioners, and physician assistants trained and approved to prescribe it.

In 2016, there were 69 OASAS-certified opioid treatment programs in NYC with a capacity to dispense methadone to approximately 32,000 patients with opioid use disorders.

(...) Most new patients in methadone treatment were Latino and Black or African-American (50% and 20%, respectively). One in three (27%) new patients in methadone treatment were White.

https://www1.nyc.gov/assets/doh/downloads/pdf/epi/databrief96.pdf

A Clinical Study of Opioid Substitution Therapy in a Tertiary Care Center of Eastern India.

Mohapatra S, Nayak MR, Dash M.

Indian J Psychol Med. 2017 Nov-Dec;39(6):756-759. doi: 10.4103/IJPSYM.IJPSYM_61_17.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733424/

A cross-national analysis of the association between years of implementation of opioid substitution treatments and drug-related deaths in Europe from 1995 to 2013.

Marotta PL, McCullagh CA.

Eur J Epidemiol. 2017 Dec 12. doi: 10.1007/s10654-017-0342-z.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29234968

Opiate agonist treatment to improve health of individuals with opioid use disorder in Lebanon.

Ghaddar A, Abbas Z, Haddad R.

Harm Reduct J. 2017 Dec 8;14(1):78. doi: 10.1186/s12954-017-0204-8.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721516/

Difficult-to-reach target groups in addiction aid - what efforts are already taken in Switzerland and what need for action remains?

Stefanie Knocks, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017

http://www.emcdda.europa.eu/system/files/attachments/7558/14H30_2_Stefanie Knocks.pptx

Kanada. B.C. pilot project to distribute clean opioids to people at high risk of overdose

Ottawa has approved a pilot project that will allow health officials in B.C. to distribute clean opioids to drug users to use as they please, marking one of the province's most radical efforts to address a fentanyl-saturated drug supply that has killed more than 1,000 people this year. (Globe and Mail, 19.12.2017)

https://www.theglobeandmail.com/news/british-columbia/bc-pilot-project-to-distribute-clean-opioids-to-people-at-high-risk-of-overdose/article37392053

Mortality and causes of death in an ageing Norwegian OMT cohort

Ivar Skeie, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017

http://www.emcdda.europa.eu/system/files/attachments/6857/12H45_00_Ivar Skeie.pptx

The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom

Matthew Hickman, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017

http://www.emcdda.europa.eu/system/files/attachments/6872/12H45_4_Matthew Hickman.ppt

Towards a long-term perspective: analysis of treatment participation in opioid substitution therapy in four European regions

Carlos Nordt, University of Zurich, Department for Psychiatry, Psychotherapy and Psychosomatics

Centre for Addictive Disorders

German Medical Association, Berlin, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017

http://www.emcdda.europa.eu/system/files/attachments/7472/11H00_5_Carlos Nordt.pdf

USA. Older Adults with Opioid Use Disorders—The Forgotten Generation

They’ve been called a “growing and understudied population”—people who need treatment, yet find it hard to obtain or to pay for. So, many do without it. And, as time passes, they become increasingly vulnerable to physical and mental challenges.

Who are they? They’re older adults who have opioid use disorders (OUDs).

Recommendations from medical and government sources on what to do to help them—evidence-based guidelines, supportive policies, even general suggestions on making treatment available to this group—are sorely lacking. (atforum, USA, 13.12.2017)

http://atforum.com/2017/12/older-adults-opioid-use-disorders-forgotten-generation/

Opioid Agonist Treatment Reduces Societal Costs of Crime

Patients with opioid use disorder generated crime-related costs to society at a lower rate while they were in treatment compared with after they left treatment.

Patients who initiate time-unlimited opioid-agonist therapy will generate lower average total crime-related costs over the next 6 months than patients who initiate a 21-day detoxification regimen.

Savings in crime-related costs are substantial and warrant inclusion in cost-effectiveness analyses of treatment for opioid addiction. (NIDA Notes, Eric Sarlin, M.Ed., M.A., 23.08.2017)

https://www.drugabuse.gov/news-events/nida-notes/2017/08/opioid-agonist-treatment-reduces-societal-costs-crime

Russland/Ukraine. Death by disdain: the fate of drug users in Russian-occupied territories

With replacement therapy now illegal, drug users in Russian-occupied Crimea and the self-proclaimed republics of the Donbas are finding it hard to survive.

(...) Yevgeny Bryun, told oDR that “methadone therapy is just a business,” and that Russia will never have such programmes.

For addicts from Crimea and eastern Ukraine, Russian jurisdiction spelt disaster. (OdR - Open Democracy Net, 11.12.2017)

https://www.opendemocracy.net/od-russia/anastasia-platonova/crimea-ukraine-drug-users-fate

Ukraine. A Blind Spot in the Movement Against Gender-Based Violence

When Yulia, the coordinator of the women’s outreach program at a harm reduction service in Kiev, Ukraine, noticed a young client’s relationship with her partner was becoming increasingly violent, she called the local government-run women’s shelter for help. The reply was short: “Does she use drugs or alcohol? Yes? Then we cannot take her.”

The shelter eventually agreed to admit the woman on the condition that she enroll in a methadone program and stop using illegal drugs. But Yulia remains worried: “Even if he lets her, enrolling into drug treatment will take weeks, while I need to get her into safety tonight. And I cannot call the police: instead of protection, she will get arrested because she is a drug user.”

Yulia’s client is not alone. According to the World Health Organization, one in three women will experience violence in her life, most commonly at the hand of an intimate partner. But for women who use drugs, this number is closer to 76 percent, like in Indonesia, or 80 percent, like in Kyrgyzstan—where half of the women surveyed also named the police among their abusers. (OSF, 08.12.2017)

https://www.opensocietyfoundations.org/voices/blind-spot-movement-against-gender-based-violence

A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence.

Chetty M, Kenworthy JJ, Langham S, Walker A, Dunlop WC.

Addict Sci Clin Pract. 2017 Feb 24;12(1):6. doi: 10.1186/s13722-017-0071-3. Review.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324212/

Kanada. B.C. to reimburse methadone patients for taking clinic fees off welfare cheques

VANCOUVER — The British Columbia government has agreed to pay back more than $5.5 million in fees deducted from the monthly social assistance cheques of methadone patients, a document filed in B.C. Supreme Court says. (The Province/The Canadian Press, 22.11.2017)

http://theprovince.com/pmn/news-pmn/canada-news-pmn/b-c-to-reimburse-methadone-patients-for-taking-clinic-fees-off-welfare-cheques/wcm/1ccd95be-5140-4489-bb59-1e7e21d200d8

How to improve Opioid Substitution Therapy implementation – Experiences from EU countries, part of a joint EAHC-WHO project involving Bulgaria, Estonia, Germany, Latvia, Lithuania, Poland, Portugal and Romania

WHO, Regional Office for Europe, 2014

http://www.euro.who.int/__data/assets/pdf_file/0015/241341/How-to-improve-Opioid-Substitution-Therapy-implementation.pdf

Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California.

Emanuel Krebs, Benjamin Enns, Elizabeth Evans, Darren Urada, M. Douglas Anglin, Richard A. Rawson, et al.

Ann Intern Med. [Epub ahead of print 21 November 2017] doi: 10.7326/M17-0611

Abstract

http://annals.org/aim/article-abstract/2664093/cost-effectiveness-publicly-funded-treatment-opioid-use-disorder-california

USA. MEDICATION-ASSISTED TREATMENT - An eBook for Parents & Caregivers of Teens & Young Adults Addicted to Opioids.

Is your teen or young adult addicted to opioids such as prescription painkillers or heroin? Medication-assisted treatment may be helpful for your child. This eBook will help you learn more about medication-assisted treatment – what it is, how it’s used, where to find it and how you can best support your child through treatment. (Partnership for Drug-Free Kids, USA, 2017

https://drugfree.org/wp-content/uploads/2017/02/Medication-Assisted-Treatment-ebook.pdf

USA. New care model closes significant gap in addiction treatment

Study finds inpatient addiction consult service helps engage patients in medication treatment. (Boston Medical Center, 08.11.2017)

https://www.eurekalert.org/pub_releases/2017-11/bmc-ncm110817.php

Stretching the Scope - Becoming Frontline Addiction-Medicine Providers.

Rapoport AB, Rowley CF.

N Engl J Med. 2017 Aug 24;377(8):705-707. doi: 10.1056/NEJMp1706492.

http://www.nejm.org/doi/full/10.1056/NEJMp1706492

Primary care models for treating opioid use disorders: What actually works? A systematic review.

Lagisetty P, Klasa K, Bush C, Heisler M, Chopra V, Bohnert A (2017)

PLoS ONE12(10): e0186315. https://doi.org/10.1371/journal.pone.0186315

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0186315

USA. Methadone Maintenance Plus

It’s the basic unit of most drug-free approaches. What would happen if it could be incorporated into the OTP curriculum?

(...) The FMS and IRETA staff decided to pilot a closed, 12 week group experience built around structured Cognitive Behavioral Therapies (CBT). Some of the activities were based on William White’s Recovery Oriented Methadone Maintenance... (Treatment and Recovery Systems, USA, 26.10.2017)

https://treatmentandrecoverysystems.com/blogs/tips-for-treatment-programs/methadone-maintenance-plus

Recovery –Oriented Methadone Maintenance

William L. White, MA; Lisa Mojer-Torres, JD;

Great Lakes Addiction Technology Transfer Center, Philadelphia Department of Behavioral Health and Mental Retardation Services, Northeast Addiction Technology Transfer Center, 2010

http://www.williamwhitepapers.com/pr/__books/full_texts/2010Recovery_orientedMethadoneMaintenance.pdf

Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys.

Degenhardt L, Glantz M, Evans-Lacko S, Sadikova E, Sampson N, Thornicroft G, Aguilar-Gaxiola S, Al-Hamzawi A, Alonso J, Helena Andrade L, Bruffaerts R, Bunting B, Bromet EJ, Miguel Caldas de Almeida J, de Girolamo G, Florescu S, Gureje O, Maria Haro J, Huang Y, Karam A, Karam EG, Kiejna A, Lee S, Lepine JP, Levinson D, Elena Medina-Mora M, Nakamura Y, Navarro-Mateu F, Pennell BE, Posada-Villa J, Scott K, Stein DJ, Ten Have M, Torres Y, Zarkov Z, Chatterji S, Kessler RC; World Health Organization's World Mental Health Surveys collaborators.

World Psychiatry. 2017 Oct;16(3):299-307. doi: 10.1002/wps.20457.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608813/